Skip to main content

News

BPL receives orphan drug marketing authorization for Coagadex® in Mexico

04 May 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today it has received orphan drug marketing authorization for Coagadex® in Mexico.

Read full article

BPL Plasma opens its 29th donor centre

22 April 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, are pleased to announce that on 22 April, BPL Plasma opened its 29th plasma donation centre.

Read full article

BPL Celebrates World Hemophilia Day 2022

17 April 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, joins the global bleeding disorders community in recognition of World Hemophilia Day (WHD). Observed annually on 17 April, WHD honours Frank Schnabel’s birthday, a person who suffered from severe hemophilia, and subsequently established the World Federation of Hemophilia (WFH).

Read full article

BPL Marks Bleeding Disorders Awareness Month 2022

31 March 2022

Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today marks the end of Bleeding Disorders Awareness Month1. Recognised every March, this month aims to help raise awareness of inheritable blood and bleeding disorders and the 300 million people affected by them worldwide.

Read full article

BPL granted a new patent in the US

30 March 2022

The United States Patent and Trademark Office granted a new patent (US Patent number: 11,149,079) to BPL for its ‘E+I’ process, granted in the US.

Read full article

BPL Supports Rare Disease Day 2022

28 February 2022

Bio Products Laboratory (“BPL”), a leading manufacturer of plasma-derived protein therapies, celebrates Rare Disease Day in recognition of the critical role it plays in raising awareness for the 300 million people worldwide living with a rare disease, their families and their carers.

Read full article

BPL Full Year 2021 Results: BPL delivers another strong performance

07 February 2022

Bio Products Laboratory (“BPL”) issues an update on its financial results and operational highlights for the 12 months ended 31 December 2021, including the more recent developments since first half trading update issued in July.

Read full article

BPL affiliate makes first ever sale to Mexico

04 February 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced its first ever direct sale in Mexico as part of an important supply award of Zenalb® 20%.

Read full article

BPL granted licence from the National Medical Products Administration (NMPA) to market ALBUMINEX® 25% product to China

24 January 2022

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced today that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.

Read full article